europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

EuropaBio Statement on Rare Disease Day

28/02/2022
OTHER
EuropaBio Statement on Rare Disease Day

February 2022

More than 300 million people worldwide, and 30 million in Europe, live with a rare disease. On Rare Disease Day, EuropaBio and its members are very proud to be part of the solution for patients.

Europe has created a thriving research and innovation community to address the rarest of diseases, and changed the lives of adults and children worldwide. It has built upon this significant research foundation with SMEs focussed into rare diseases, bringing the skills and investment needed for development of therapies. In this context, Europe needs to continue to promote a stable regulatory environment to foster innovation in the area of rare diseases.

We need to fully empower this innovation engine and pipeline by unlocking more public and private funding for start ups and SMEs, enhancing the conditions for R&D productivity, and implementing coherent long term market access conditions for a competitive Europe.

EuropaBio makes the call:

• European Union, Member States, plus public and private stakeholders must work together towards accessible therapies for rare disease patients

• Foster rare disease ecosystems and translate cutting edge European research into solutions for unmet medical needs

• Boost investment into basic research, to deliver the scientific advances from which Europe fills its innovation pipeline, particularly in cell and gene therapies – delivering the science, infrastructure and skills that underpin next generation healthcare

• Enable and harness the full strength and industrial collaboration potential of European Reference Networks for maximum benefit to rare disease patients across Europe

• Ensure appropriate incentives that stimulate competition amongst innovators and reward risk, for commitment to rare disease pipelines in companies large and small

EuropaBio Statement on Rare Disease Day


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
16/01/2023

SwiftPharma joins EuropaBio: pioneering sustainable, scalable and affordable plant-made therapeutic proteins


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies